Exscientia Shareholders Greenlight AGM Proposals
Exscientia (EXAI) Upgraded to Buy: Here's What You Should Know
Barclays Maintains Exscientia(EXAI.US) With Buy Rating, Maintains Target Price $10
Barclays analyst Peter Lawson maintains $Exscientia(EXAI.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 44.1% and a total a
Barclays Keeps Their Buy Rating on Exscientia Plc (EXAI)
Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon
Health care stocks were edging up Tuesday afternoon, with the NYSE Health Care Index rising 0.2% and the Health Care Select Sector SPDR Fund (XLV) fractionally higher. The iShares Biotechnology ETF (I
Exscientia to Reduce Up to 25% Workforce by Year End
Exscientia (EXAI) said Tuesday that it expects to complete a headcount reduction of 20% to 25% by the end of 2024. The job cuts are part of cost efficiency measures that the company will initiate to s
Exscientia Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Sales Results.
Exscientia Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Sales Results.
Tandem Diabetes Care, Guardion Health, GT Biopharma Among Healthcare Movers
Exscientia Advances AI-Driven Drug Pipeline, Cuts Costs
Exscientia | 6-K: Report of foreign private issuer (related to financial reporting)
Exscientia's Cash, Cash Equivalents And Short-term Bank Deposits As Of March 31, 2024 Were $416.9M, Which Is Expected To Provide Cash Runway Into 2027
Exscientia's Cash, Cash Equivalents And Short-term Bank Deposits As Of March 31, 2024 Were $416.9M, Which Is Expected To Provide Cash Runway Into 2027
Exscientia 1Q Rev $6.7M >EXAI
Exscientia 1Q Rev $6.7M >EXAI
Exscientia Believes Cash, Cash Equivalents, Short-Term Bank Deposits, Anticipated Milestones Will Be Sufficient to Fund Ops Well Into 2027 >EXAI
Exscientia Believes Cash, Cash Equivalents, Short-Term Bank Deposits, Anticipated Milestones Will Be Sufficient to Fund Ops Well Into 2027 >EXAI
Earnings Flash (EXAI) EXSCIENTIA Reports Q1 Revenue $6.7M
07:04 AM EDT, 05/21/2024 (MT Newswires) -- Earnings Flash (EXAI) EXSCIENTIA Reports Q1 Revenue $6.7M
Exscientia Q1 2024 GAAP EPS $(0.21) Beats $(0.39) Estimate, Sales $6.700M Miss $7.509M Estimate
Exscientia Q1 2024 GAAP EPS $(0.21) Beats $(0.39) Estimate, Sales $6.700M Miss $7.509M Estimate
Exscientia: LSD1 and MALT1 Inhibitor Programmes Expected to Advance Into Clinic in 2H24 and Early 2025, Respectively >EXAI
Exscientia: LSD1 and MALT1 Inhibitor Programmes Expected to Advance Into Clinic in 2H24 and Early 2025, Respectively >EXAI
Exscientia: GTAEXS617 (CDK7 Inhibitor) Initial Phase I Data Expected in 2H24 >EXAI
Exscientia: GTAEXS617 (CDK7 Inhibitor) Initial Phase I Data Expected in 2H24 >EXAI
Press Release: Exscientia Business Update for First Quarter 2024
Exscientia Business Update for First Quarter 2024 Positive early Phase 1 results for BMS-partnered programme '4318 (PKC-theta inhibitor) GTAEXS617 (CDK7 inhibitor) initial Phase I data expected in 2
Exscientia to Report First Quarter 2024 Financial Results on May 21, 2024
Company to host conference call and webcast on May 21, 2024, at 1:30 p.m. BST / 8:30 a.m. EDTOXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) will report financial results for the first
Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Nasdaq Composite jumping over 50 points on Monday.Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply during Monday's session on reports the company will partner with Ba